Search

Your search keyword '"Narayan, Vivek"' showing total 578 results
Start Over Author "Narayan, Vivek"
578 results on '"Narayan, Vivek"'

2. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.

Author

Lin, John, Hearn, Caleb, Getzen, Emily, Long, Qi, Lee, David, Keaveny, Tony, Jayadevappa, Ravishankar, Robinson, Kyle, Wong, Yu-Ning, Maxwell, Kara, Narayan, Vivek, Haas, Naomi, Takvorian, Samuel, Bikle, Daniel, Chiang, Janet, Khan, Amna, Rajapakse, Chamith, Morgans, Alicia, and Parikh, Ravi

Subjects
Androgen deprivation therapy, Antiresorptive therapy, Biomechanical computed tomography, Dual x-ray absorptiometry, Fracture, Prostate cancer, Humans, Male, Prostatic Neoplasms, Aged, Retrospective Studies, Bone Density, Tomography, X-Ray Computed, Risk Assessment, Fractures, Bone, Middle Aged, Androgen Antagonists, Absorptiometry, Photon, Cohort Studies, Biomechanical Phenomena
Abstract

BACKGROUND: Guidelines recommend dual-energy x-ray absorptiometry (DXA) screening to assess fracture risk and benefit from antiresorptive therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) on androgen deprivation therapy (ADT). However,

Published
2024

4. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.

Author

Eule, Corbin, Hu, Junxiao, Al-Saad, Sulaiman, Collier, Katharine, Boland, Patrick, Lewis, Akeem, Narayan, Vivek, Bosse, Dominick, Mortazavi, Amir, Rose, Tracy, Costello, Brian, Bryce, Alan, Lam, Elaine, and Mckay, Rana

Subjects
Chemotherapy, Small cell, Male, Humans, Middle Aged, Aged, Prostate-Specific Antigen, Retrospective Studies, Platinum, Prostatic Neoplasms, Prognosis
Abstract

BACKGROUND: De novo neuroendocrine prostate cancer (NEPC) and treatment-emergent neuroendocrine prostate cancer (T-NEPC) are rare diseases with a poor prognosis. After first-line platinum chemotherapy, there is no consensus on second-line treatments. PATIENTS AND METHODS: Patients with a pathologic diagnosis of de novo NEPC or T-NEPC between 2000 and 2020 who received first-line platinum and any second-line systemic therapy were selected and standardized clinical data was collected via the electronic health record at each institution. The primary endpoint was overall survival (OS) based on second-line therapy. Secondary endpoints included objective response rate (ORR) to second-line therapy, PSA response, and time on treatment. RESULTS: Fifty-eight patients (32 de novo NEPC, 26 T-NEPC) from 8 institutions were included. At de novo NEPC or T-NEPC diagnosis, the overall cohort had a median age of 65.0 years (IQR 59.2-70.3) and median PSA of 3.0 ng/dL (IQR 0.6-17.9). Following first-line platinum chemotherapy, 21 patients (36.2%) received platinum chemotherapy, 10 (17.2%) taxane monotherapy, 11 (19.0%) immunotherapy, 10 (17.2%) other chemotherapy, and 6 (16.2%) other systemic therapy. Among 41 evaluable patients, the ORR was 23.5%. The mOS after start of second-line therapy was 7.4 months (95% CI 6.1-11.9). CONCLUSIONS: In this retrospective study, patients with de novo NEPC or T-NEPC who received second-line therapy were treated with wide variety of treatment regimens, reflecting the lack of consensus in this setting. Most patients received chemotherapy-based treatments. Overall prognosis was poor and ORR was low in the second line regardless of treatment choice.

Published
2023

7. Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer

Author

Demissei, Biniyam G., Ko, Kyunga, Huang, Anran, Lee, Daniel J., Doucette, Abigail G., Smith, Amanda M., Wilcox, Nicholas S., Reibel, Jacob, Sun, Lova, Agarwal, Manuj, Haas, Naomi B., Hollis, Genevieve, Shpilsky, Jason E., Takvorian, Samuel U., Vaughn, David J., Chen, Jinbo, Hubbard, Rebecca A., Powell-Wiley, Tiffany, Yancy, Clyde, Narayan, Vivek, and Ky, Bonnie

Published
2024
Full Text
View/download PDF

9. Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity

Author

Chaudhary, Omkar, Wang, Lingyun, Bose, Deepanwita, Narayan, Vivek, Yeh, Ming Te, Carville, Angela, Clements, John D, Andino, Raul, Kozlowski, Pamela A, and Aldovini, Anna

Subjects
Rare Diseases, Immunization, Vaccine Related, Infectious Diseases, Prevention, HIV/AIDS, Biotechnology, Vaccine Related (AIDS), Dental/Oral and Craniofacial Disease, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Viral, Escherichia coli, Female, HIV Infections, Humans, Leukocytes, Mononuclear, Macaca mulatta, Mouth, SAIDS Vaccines, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Vaccination, Vaccinia virus, AIDS, SIV vaccine, DNA vaccine, mucosal immunity, Simian immunodeficiency virus, Clinical Sciences, Virology
Abstract

Attempts to develop a protective human immunodeficiency virus (HIV) vaccine have had limited success, especially in terms of inducing protective antibodies capable of neutralizing different viral strains. As HIV transmission occurs mainly via mucosal surfaces, HIV replicates significantly in the gastrointestinal tract, and the oral route of vaccination is a very convenient one to implement worldwide, we explored three SIV vaccine modalities administered orally and composed of simian immunodeficiency virus (SIV) DNA priming with different boosting immunogens, with the goal of evaluating whether they could provide lasting humoral and cellular responses, including at mucosal surfaces that are sites of HIV entry. Twenty-four Cynomolgus macaques (CyM) were primed with replication-incompetent SIV DNA provirus and divided into three groups for the following booster vaccinations, all administered in the oral cavity: Group 1 with recombinant SIV gp140 and Escherichia coli heat-labile toxin adjuvant dmLT, Group 2 with recombinant SIV-Oral Poliovirus (SIV-OPV), and Group 3 with recombinant SIV-modified vaccinia ankara (SIV-MVA). Cell-mediated responses were measured using blood, lymph node, rectal and vaginal mononuclear cells. Significant levels of systemic and mucosal T-cell responses against Gag and Env were observed in all groups. Some SIV-specific plasma IgG, rectal and salivary IgA antibodies were generated, mainly in animals that received SIV DNA + SIV-MVA, but no vaginal IgA was detected. Susceptibility to infection after SIVmac251 challenge was similar in vaccinated and nonvaccinated animals, but acute infection viremia levels were lower in the group that received SIV DNA + SIV-MVA. Nonvaccinated CyM maintained central memory and total CD4+ T-cell levels in the normal range during the 5 months of postinfection follow-up as did the vaccinated animals, precluding evaluation of vaccine impact on disease progression. We conclude that the oral cavity vaccination tested in these regimens can stimulate cell-mediated immunity systemically and mucosally, but humoral response stimulation was limited with the doses and the vaccine platforms used.

Published
2020

10. Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

Author

Duarte, Cassandra, Hu, Junxiao, Beuselinck, Benoit, Panian, Justine, Weise, Nicole, Dizman, Nazli, Collier, Katharine A., Rathi, Nityam, Li, Haoran, Elias, Roy, Martinez-Chanza, Nieves, Rose, Tracy L., Harshman, Lauren C., Gopalakrishnan, Dharmesh, Vaishampayan, Ulka, Zakharia, Yousef, Narayan, Vivek, Carneiro, Benedito A., Mega, Anthony, Singla, Nirmish, Meguid, Cheryl, George, Saby, Brugarolas, James, Agarwal, Neeraj, Mortazavi, Amir, Pal, Sumanta, McKay, Rana R., and Lam, Elaine T.

Published
2023
Full Text
View/download PDF

12. Supplementary Table 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Table 3 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

18. Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, primary, Iliopoulos, Othon, primary, Beckermann, Kathryn E., primary, Narayan, Vivek, primary, Maughan, Benjamin L., primary, Oudard, Stephane, primary, Maranchie, Jodi K., primary, Iversen, Ane B., primary, Goldberg, Cynthia M., primary, Fu, Wei, primary, Perini, Rodolfo F., primary, Liu, Yanfang, primary, Linehan, W. Marston, primary, and Srinivasan, Ramaprasad, primary

Published
2024
Full Text
View/download PDF

19. Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Author

Else, Tobias, primary, Jonasch, Eric, additional, Iliopoulos, Othon, additional, Beckermann, Kathryn E., additional, Narayan, Vivek, additional, Maughan, Benjamin L., additional, Oudard, Stephane, additional, Maranchie, Jodi K., additional, Iversen, Ane B., additional, Goldberg, Cynthia M., additional, Fu, Wei, additional, Perini, Rodolfo F., additional, Liu, Yanfang, additional, Linehan, W. Marston, additional, and Srinivasan, Ramaprasad, additional

Published
2024
Full Text
View/download PDF

20. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Author

Narayan, Vivek, Barber-Rotenberg, Julie S., Jung, In-Young, Lacey, Simon F., Rech, Andrew J., Davis, Megan M., Hwang, Wei-Ting, Lal, Priti, Carpenter, Erica L., Maude, Shannon L., Plesa, Gabriela, Vapiwala, Neha, Chew, Anne, Moniak, Michael, Sebro, Ronnie A., Farwell, Michael D., Marshall, Amy, Gilmore, Joan, Lledo, Lester, Dengel, Karen, Church, Sarah E., Hether, Tyler D., Xu, Jun, Gohil, Mercy, Buckingham, Thomas H., Yee, Stephanie S., Gonzalez, Vanessa E., Kulikovskaya, Irina, Chen, Fang, Tian, Lifeng, Tien, Kyle, Gladney, Whitney, Nobles, Christopher L., Raymond, Hayley E., Hexner, Elizabeth O., Siegel, Donald L., Bushman, Frederic D., June, Carl H., Fraietta, Joseph A., and Haas, Naomi B.

Published
2022
Full Text
View/download PDF

22. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer

Author

Lee, Daniel J., Hausler, Ryan, Le, Anh N., Kelly, Gregory, Powers, Jacquelyn, Ding, James, Feld, Emily, Desai, Heena, Morrison, Casey, Doucette, Abigail, Gabriel, Peter, Genetics Center, Regeneron, Judy, Renae L., Weaver, Joellen, Kember, Rachel, Damrauer, Scott M., Rader, Daniel J., Domchek, Susan M., Narayan, Vivek, Schwartz, Lauren E., and Maxwell, Kara N.

Published
2022
Full Text
View/download PDF

27. Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Author

Zorko, Nicholas A., primary, Makovec, Allison, additional, Elliott, Andrew, additional, Kellen, Samuel, additional, Lozada, John R., additional, Arafa, Ali T., additional, Felices, Martin, additional, Shackelford, Madison, additional, Barata, Pedro, additional, Zakharia, Yousef, additional, Narayan, Vivek, additional, Stein, Mark N., additional, Zarrabi, Kevin K., additional, Patniak, Akash, additional, Bilen, Mehmet A., additional, Radovich, Milan, additional, Sledge, George, additional, El-Deiry, Wafik S., additional, Heath, Elisabeth I., additional, Hoon, Dave S. B., additional, Nabhan, Chadi, additional, Miller, Jeffrey S., additional, Hwang, Justin H., additional, and Antonarakis, Emmanuel S., additional

Published
2024
Full Text
View/download PDF

34. CTNI-71. BELZUTIFAN FOR VON HIPPEL-LINDAU DISEASE-RELATED CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS: SUBGROUP OF PHASE 2 LITESPARK-004 STUDY

Author

Iliopoulos, Othon, primary, Iversen, Ane B, additional, Narayan, Vivek, additional, Maughan, Benjamin L, additional, Beckermann, Kathryn E, additional, Oudard, Stephane, additional, Else, Tobias, additional, Maranchie, Jodi K, additional, Fu, Wei, additional, Perini, Rodolfo F, additional, Liu, Yanfang, additional, Linehan, W Marston, additional, Srinivasan, Srinivasan, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

35. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs

Author

Narayan, Vivek, primary, Liu, Tao, additional, Song, Yunjie, additional, Mitchell, Joshua, additional, Sicks, JoRean, additional, Gareen, Ilana, additional, Sun, Lova, additional, Denduluri, Srinivas, additional, Fisher, Ciaran, additional, Manikowski, Jesse, additional, Wojtowicz, Mark, additional, Vadakara, Joseph, additional, Haas, Naomi, additional, Margulies, Kenneth B., additional, and Ky, Bonnie, additional

Published
2023
Full Text
View/download PDF

38. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Author

Martínez Chanzá, Nieves, Xie, Wanling, Asim Bilen, Mehmet, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, and Harshman, Lauren C

Published
2019
Full Text
View/download PDF

41. Effect of erythropoietin-stimulating agent use on belzutifan antitumor activity in patients with VHL disease–associated renal cell carcinoma: Post hoc analysis of the LITESPARK-004 study.

Author

Maughan, Benjamin L., Srinivasan, Ramaprasad, Iliopoulos, Othon, Bundsbæk Bøndergaard Iversen, Ane, Narayan, Vivek, Oudard, Stephane, Else, Tobias, Maranchie, Jodi K., Beckermann, Katy, Fu, Wei, Perini, Rodolfo F., Liu, Yanfang, Linehan, W. Marston, and Jonasch, Eric

Published
2024
Full Text
View/download PDF

42. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

43. SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY

Author

Narayan, Vivek, primary, Iliopoulos, Othon, additional, Iversen, Ane B, additional, Maughan, Benjamin L, additional, Beckermann, Kathryn E, additional, Oudard, Stephane, additional, Else, Tobias, additional, Maranchie, Jodi K, additional, Fu, Wei, additional, Perini, Rodolfo F, additional, Liu, Yanfang, additional, Linehan, W Marston, additional, Srinivasan, Ramaprasad, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

44. Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction

Author

Jung, In-Young, primary, Bartoszek, Robert L., primary, Rech, Andrew J., primary, Collins, Sierra M., primary, Ooi, Soon-Keat, primary, Williams, Erik F., primary, Hopkins, Caitlin R., primary, Narayan, Vivek, primary, Haas, Naomi B., primary, Frey, Noelle V., primary, Hexner, Elizabeth O., primary, Siegel, Donald L., primary, Plesa, Gabriela, primary, Porter, David L., primary, Cantu, Adrian, primary, Everett, John K., primary, Guedan, Sonia, primary, Berger, Shelley L., primary, Bushman, Frederic D., primary, Herbst, Friederike, primary, and Fraietta, Joseph A., primary

Published
2023
Full Text
View/download PDF

45. Data from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction

Author

Jung, In-Young, primary, Bartoszek, Robert L., primary, Rech, Andrew J., primary, Collins, Sierra M., primary, Ooi, Soon-Keat, primary, Williams, Erik F., primary, Hopkins, Caitlin R., primary, Narayan, Vivek, primary, Haas, Naomi B., primary, Frey, Noelle V., primary, Hexner, Elizabeth O., primary, Siegel, Donald L., primary, Plesa, Gabriela, primary, Porter, David L., primary, Cantu, Adrian, primary, Everett, John K., primary, Guedan, Sonia, primary, Berger, Shelley L., primary, Bushman, Frederic D., primary, Herbst, Friederike, primary, and Fraietta, Joseph A., primary

Published
2023
Full Text
View/download PDF

46. Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction

Author

Jung, In-Young, primary, Bartoszek, Robert L., primary, Rech, Andrew J., primary, Collins, Sierra M., primary, Ooi, Soon-Keat, primary, Williams, Erik F., primary, Hopkins, Caitlin R., primary, Narayan, Vivek, primary, Haas, Naomi B., primary, Frey, Noelle V., primary, Hexner, Elizabeth O., primary, Siegel, Donald L., primary, Plesa, Gabriela, primary, Porter, David L., primary, Cantu, Adrian, primary, Everett, John K., primary, Guedan, Sonia, primary, Berger, Shelley L., primary, Bushman, Frederic D., primary, Herbst, Friederike, primary, and Fraietta, Joseph A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results